CA2426069A1 - Treatment of anxiety disorders - Google Patents
Treatment of anxiety disorders Download PDFInfo
- Publication number
- CA2426069A1 CA2426069A1 CA002426069A CA2426069A CA2426069A1 CA 2426069 A1 CA2426069 A1 CA 2426069A1 CA 002426069 A CA002426069 A CA 002426069A CA 2426069 A CA2426069 A CA 2426069A CA 2426069 A1 CA2426069 A1 CA 2426069A1
- Authority
- CA
- Canada
- Prior art keywords
- norepinephrine reuptake
- reuptake inhibitor
- dsm
- disorder
- anxiety disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24901000P | 2000-11-15 | 2000-11-15 | |
| US60/249,010 | 2000-11-15 | ||
| US26536201P | 2001-01-31 | 2001-01-31 | |
| US60/265,362 | 2001-01-31 | ||
| PCT/US2001/027801 WO2002040006A2 (en) | 2000-11-15 | 2001-11-06 | Treatment of anxiety disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2426069A1 true CA2426069A1 (en) | 2002-05-23 |
Family
ID=26939750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002426069A Abandoned CA2426069A1 (en) | 2000-11-15 | 2001-11-06 | Treatment of anxiety disorders |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1395253A2 (pt) |
| JP (1) | JP2004529073A (pt) |
| KR (1) | KR20030051812A (pt) |
| CN (1) | CN1822825A (pt) |
| AU (1) | AU2002217757A1 (pt) |
| BR (1) | BR0115301A (pt) |
| CA (1) | CA2426069A1 (pt) |
| CZ (1) | CZ20031339A3 (pt) |
| EA (1) | EA200300567A1 (pt) |
| HR (1) | HRP20030384A2 (pt) |
| IL (1) | IL155874A0 (pt) |
| MX (1) | MXPA03004190A (pt) |
| NO (1) | NO20032156L (pt) |
| PL (1) | PL366119A1 (pt) |
| SK (1) | SK5422003A3 (pt) |
| WO (1) | WO2002040006A2 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2201942B2 (es) * | 2001-03-06 | 2004-12-16 | Eli Lilly And Company | Inhibidor de la captacion de monoamina. |
| WO2004016272A1 (en) * | 2002-08-14 | 2004-02-26 | Pharmacia & Upjohn Company Llc | Use of reboxetine for the treatment of hot flashes |
| GB0309440D0 (en) * | 2003-04-25 | 2003-06-04 | Lilly Co Eli | Quinolone derivatives |
| WO2004103356A2 (en) * | 2003-05-15 | 2004-12-02 | Eli Lilly And Company | Treatment of emotional dysregulation |
| CA2548304A1 (en) * | 2003-12-12 | 2005-07-07 | Eli Lilly And Company | Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition |
| WO2009089479A2 (en) * | 2008-01-09 | 2009-07-16 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
| WO2011056788A2 (en) * | 2009-11-03 | 2011-05-12 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
| WO2011056773A2 (en) * | 2009-11-03 | 2011-05-12 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
| WO2014159251A2 (en) | 2013-03-14 | 2014-10-02 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
| JP2022519541A (ja) * | 2019-02-01 | 2022-03-24 | ホフマン・テクノロジーズ・エルエルシー | 不安関連障害を処置するための組成物および方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2931997A (en) * | 1996-05-07 | 1997-11-26 | Merck & Co., Inc. | Treatment of mood disorders with a growth hormone secretagogue |
| IT1305322B1 (it) * | 1998-04-23 | 2001-05-04 | Pharmacia & Upjohn Spa | Uso di reboxetina per il trattamento di disturbi nervosi |
| ES2242175T3 (es) * | 1999-07-01 | 2005-11-01 | PHARMACIA & UPJOHN COMPANY LLC | (s,s)-reboxetina para tratar la fibromialgia y otros trastornos somatoformes. |
-
2001
- 2001-11-06 AU AU2002217757A patent/AU2002217757A1/en not_active Abandoned
- 2001-11-06 BR BR0115301-3A patent/BR0115301A/pt not_active IP Right Cessation
- 2001-11-06 EA EA200300567A patent/EA200300567A1/ru unknown
- 2001-11-06 CN CNA01818927XA patent/CN1822825A/zh active Pending
- 2001-11-06 KR KR10-2003-7006523A patent/KR20030051812A/ko not_active Application Discontinuation
- 2001-11-06 PL PL01366119A patent/PL366119A1/xx not_active Application Discontinuation
- 2001-11-06 SK SK542-2003A patent/SK5422003A3/sk not_active Application Discontinuation
- 2001-11-06 WO PCT/US2001/027801 patent/WO2002040006A2/en not_active Application Discontinuation
- 2001-11-06 IL IL15587401A patent/IL155874A0/xx unknown
- 2001-11-06 MX MXPA03004190A patent/MXPA03004190A/es unknown
- 2001-11-06 CA CA002426069A patent/CA2426069A1/en not_active Abandoned
- 2001-11-06 JP JP2002542380A patent/JP2004529073A/ja active Pending
- 2001-11-06 EP EP01996376A patent/EP1395253A2/en not_active Withdrawn
- 2001-11-06 CZ CZ20031339A patent/CZ20031339A3/cs unknown
-
2003
- 2003-05-13 NO NO20032156A patent/NO20032156L/no not_active Application Discontinuation
- 2003-05-14 HR HR20030384A patent/HRP20030384A2/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20032156D0 (no) | 2003-05-13 |
| IL155874A0 (en) | 2003-12-23 |
| HRP20030384A2 (en) | 2003-08-31 |
| PL366119A1 (en) | 2005-01-24 |
| SK5422003A3 (en) | 2003-12-02 |
| EP1395253A2 (en) | 2004-03-10 |
| WO2002040006A3 (en) | 2003-12-24 |
| JP2004529073A (ja) | 2004-09-24 |
| NO20032156L (no) | 2003-05-13 |
| KR20030051812A (ko) | 2003-06-25 |
| MXPA03004190A (es) | 2003-09-22 |
| CN1822825A (zh) | 2006-08-23 |
| BR0115301A (pt) | 2004-12-14 |
| CZ20031339A3 (cs) | 2003-10-15 |
| EA200300567A1 (ru) | 2004-10-28 |
| WO2002040006A2 (en) | 2002-05-23 |
| AU2002217757A1 (en) | 2002-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2304657C (en) | Treatment of conduct disorder | |
| US6028070A (en) | Treatment of oppositional defiant disorder | |
| Gillin et al. | A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial | |
| RU2488392C2 (ru) | Лечение агонистом мелатонина | |
| EA006652B1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| CA2426069A1 (en) | Treatment of anxiety disorders | |
| US20080200555A1 (en) | Use of norepinephrine reuptake inhibitors for the treatment of tic disorders | |
| US6683114B2 (en) | Treatment of psoriasis | |
| TW200300672A (en) | Treatment of cognitive failure | |
| US20040034106A1 (en) | Treatment of anxiety disorders | |
| ZA200303738B (en) | Treatment of anxiety disorders. | |
| US4443479A (en) | Pharmaceutical methods and compositions using parabenzoquinone | |
| US4522830A (en) | Pharmaceutical methods using parabenzoquinone to treat muscle spasms | |
| MXPA00002837A (en) | Treatment of oppositional defiant disorder | |
| MXPA00002829A (en) | Treatment of conduct disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |